The Mice Model Market is projected to reach $2.48 billion by 2030, at a CAGR of 6.5% from 2023 to 2030. Mice models are commonly used for studying aspects of human health & diseases. Mice are especially useful for this purpose since they have similar mammalian features to that of humans. There are different types of mice models, such as inbred mice, genetically engineered mice, hybrid/congenic mice, and conditioned/surgically modified mice. These models can be used for various applications, such as oncology, cardiology, genetic, and endocrine and metabolic studies.
The growth of this market is driven by factors such as the advantages of mice as an animal model for studying human diseases, the rising prevalence of cancer, the increasing number of grants for research studies, and the rising demand for personalized medicine. In addition, the technological advancements & innovations in mice models are expected to provide significant growth opportunities for this market.
However, ethical concerns and regulatory restrictions are expected to hinder the growth of this market to a certain extent. In addition, factors such as the lack of skilled personnel for performing animal studies and the high cost of mice models are the major challenges to the growth of this market.
Advantages of Mice as an Animal Model for Studying Human Diseases to Drive Market Growth
The mice models are the most preferred animals for research in laboratories. The genetic composition of humans and mice is very similar. In addition, the pathophysiology of diseases in mice is also similar to humans. Due to this, it is very easy and effective to conduct studies on mice models for research and drug testing.
Mice can also be genetically modified to mimic human diseases or conditions. These genetically modified mice can then be used to study the disease and test drugs on it. Additionally, mice have an accelerated life span compared to humans; due to this, the entire life cycle of mice can be studied in 2–3 years. Some other advantages they offer are cost-effectiveness; they are easy to handle, transport, and reproduce.
Thus, the advantages of mice as an animal model for studying human diseases are expected to drive the growth of the mice model market.
Click here to: Get a Free Sample Copy of this report
Increasing Prevalence of Cancer to Drive Demand for Mice Models in Cancer Research
Cancer has been one of the most complex and expensive diseases globally, with a huge economic burden on many countries. The International Agency for Research on Cancer (IARC) estimates that globally, 1 in 5 people develop cancer during their lifetimes, with 1 in 8 men and 1 in 11 women dying from the disease.
Cancer is a major cause of death and a prominent obstacle to improving life expectancy in every country worldwide. According to the International Agency for Research on Cancer (IARC), the number of new cancer cases is expected to reach 24.5 million by 2030. In addition, mortalities from cancer are expected to increase from 9.9 million in 2020 to 12.9 million by 2030.
Mice models can be used to identify the genetic causes of cancer, reproduce tumor types in mice and test new cancer therapies. Thus, the increasing prevalence of cancer is driving the use of mice models in cancer research.
Key Findings of the Mice Model Market Study:
In 2023, the Inbred Mice Segment is Expected to Dominate the Mice Model Market
Based on mice type, the mice model market is segmented into inbred mice, genetically engineered mice, outbred mice, hybrid/ congenic mice, conditioned/surgically modified mice, spontaneous mutant mice, and other types. In 2023, the inbred mice segment is expected to account for the largest share of the mice model market. Inbred mice are colonies produced by mating twenty or more generations of brother-sister pairs. This mating provides mice that are genetically identical within each inbred strain. The large market share of this segment is attributed to the increased use of inbred mice due to their advantages, such as unique and stable phenotypic traits, consistency in the test results, and predictable experiment response.
In 2023, the Breeding Segment is Expected to Dominate the Mice Model Market
Based on service, the mice model market is segmented into breeding, cryopreservation, model-in licensing, genetic testing, quarantine, and other services. In 2023, the breeding segment is expected to account for the largest share of the mice model market. The large market share of this segment is attributed to the increased demand for breeding services for providing genetically modified mice strains, the increasing number of research projects and research funding.
In 2023, the CRISPR/CAS9 Segment is Expected to Dominate the Mice Model Market
Based on technology, the mice model market is segmented into CRISPR/CAS9, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, the CRISPR/CAS9 segment is expected to account for the largest share of the mice model market. The large market share of this segment is attributed to the advantages of using this technology in genome editing for creating unique mouse models of human disease. This technology can produce mice models in a cost-effective way while saving time and potentially reducing the number of animal usage.
In 2023, the Outsourced Segment is Expected to Dominate the Mice Model Market
Based on mode, the mice model market is segmented into outsourced and in-house. In 2023, the outsourced segment is expected to account for the larger share of the mice model market. The large market share of this segment is attributed to the advantages of outsourcing mice models, such as cost savings, increased flexibility, access to specialized expertise, and availability of a large variety of models.
In 2023, the Oncology Studies Segment is Expected to Dominate the Mice Model Market
Based on application, the mice model market is segmented into oncology studies, cardiovascular studies, genetic studies, endocrine metabolic studies, neurological studies, immunology & inflammation studies, and other applications. In 2023, the oncology studies segment is expected to account for the largest share of the mice model market. The large market share of this segment is attributed to the increased prevalence of cancer, increased funding for cancer research, and advantages of using mice models in cancer research, such as the ability to physiologically imitate cancer as humans.
In 2023, the Pharmaceutical & Biotechnology Companies Segment is Expected to Dominate the Mice Model Market
Based on end user, the mice model market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. In 2023, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the mice model market. The large market share of this segment is attributed to the increased global pharmaceutical R&D expenditure, rising demand for personalized medicine, and a large number of therapeutic drug molecules in the research pipeline.
Asia-Pacific: The Fastest-growing Regional Market
Asia-Pacific is slated to record the highest CAGR in the mice model market during the forecast period. The growth of this market is driven by the rapidly growing pharmaceutical & biotechnology industry in the region, increasing R&D expenditure, and increasing government funding for research projects, especially in China and India.
Key Players
The report includes a competitive landscape based on an extensive assessment of the market based on mice type, service, technology, mode, application, end user, and geography. The report also provides insights into the geographic presence of major market players and their key growth strategies in the last three to four years.
The key players profiled in the mice model market are Charles River Laboratories International, Inc. (U.S.), The Jackson Laboratory (U.S.), Laboratory Corporation of America Holdings (U.S.), Horizon Discovery Group plc (U.K.), Trans Genic Inc. (Japan), GenOway S.A. (France), Taconic Biosciences, Inc.(U.S.), Envigo Ltd (U.S.), Janvier Labs (France), ingenious targeting laboratory (U.S.), Harbour Antibodies B.V. (China) (Subsidiary of HBM Holdings), Crescendo Biologics Ltd. (U.K.), Deltagen Inc. (U.S.), and ImmunoGenes Kft. (Hungary).
Scope of the Report:
Mice Model Market Assessment, by Mice Type
- Inbred Mice
- Genetically Engineered Mice
- Outbred Mice
- Hybrid/Congenic Mice
- Conditioned/Surgically Modified Mice
- Spontaneous Mutant Mice
- Other Types
(Other types majorly include knockout mice model, carcinogen-induced mice model, and transplantation mice model)
Mice Model Market Assessment, by Service
- Breeding
- Cryopreservation
- Model-in Licensing
- Genetic Testing
- Quarantine
- Other Services
(Other Services include in-vivo & in-vitro pharmacology, rederivation, and genetically engineered model services)
Mice Model Market Assessment, by Technology
- CRISPR/CAS9
- Embryonic Stem Cell Injection
- Nuclear Transfer
- Other Technologies
(Other Technologies majorly include microinjection and chemical mutagenesis)
Mice Model Market Assessment, by Mode
Mice Model Market Assessment, by Application
- Oncology Studies
- Cardiovascular Studies
- Genetic Studies
- Endocrine Metabolic Studies
- Neurological Studies
- Immunology & Inflammation studies
- Other Applications
(Other applications include infectious disease studies, fibrosis, and regenerative medicine)
Mice Model Market Assessment, by End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations
- Other End Users
(Other end users include cosmetic companies and government agencies)
Mice Model Market, by Geography
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
- Middle East & Africa
Key questions answered in the report:
